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1. Summary 2. Introduction 
Antitumor properties and participation i inflam- 
matory events are important characteristics of acti- 
vated macrophages. We show here that both an- 
titumor cytostatic function of macrophages and 
participation of these cells at inflammatory sites are 
controlled by two main groups of mediators: 
cytokines (IL-1, TNFot) and eicosanoids (prosta- 
noids and leukotrienes). These two groups of media- 
tors represent a complex system of mutual interac- 
tions in regulation of their production and activities. 
Multiple sets of experiments with murine macro- 
phages are discussed in favor of the views that 
PGE 2 and lipoxygenase products oppose each 
other's actions, and that the regulating role of 
PGE 2 in the secretions of cytokines are of pivotal 
importance in antitumor cytostasis of macrophages 
in vitro. Such observations can be extended to a situ- 
ation ex vivo, showing that human macrophages 
harvested from inflammatory sites have markedly 
augmented cytostatic expression. It thus appears 
that the antitumor cytostatic function of macro- 
phages is related to the production of inflammatory 
mediators by these cells. Accordingly, it might be 
that occurrence of inflammation in tumor-bearing 
individuals plays a role in the promotion of an- 
titumor activity of macrophages. 
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The concept that phagocytic cells play a role in the 
defense of the organism against foreign intruders 
was first elaborated by Metchnikoff in 1901 [1]. 
Later [2], Metchnikoff claimed also that macro- 
phages are activated in response to an inflammatory 
challenge. Such activated macrophages were found 
to exhibit high antitumor cytotoxic response [3]. 
Extensive work was done with the aim to deter- 
mine the mechanism(s) of macrophage activation. A
recent review [4] summarizes the data on cytotoxic 
activities of macrophages. The macrophage can re- 
act nonspecificaIly against a wide array of cells, in- 
cluding tumor cells. The antitumor potential of 
quiescent macrophages i  hardly appreciable, but 
with activated macrophages the expression of 
cytostatic and/or cytocidal effects toward tumor 
cells is rather pronounced [3, 4]. Macrophage- 
mediated antitumor cytostasis can be defined as the 
inhibition of tumor cell division and can be distin- 
guished from the cytocidal effect [4]. The antitumor 
function of macrophages may comprise two 
mechanisms, existing separately or concomitantly: 
(a) cell-to-cell contact between macrophages and 
tumor cells; (b) discharge of factors which attack 
target cells. Among these factors, interleukin-1 (IL- 
l) and tumor necrosis factor (TNFc0 are now recog- 
nized as mediators of inflammation [5]. Further- 
more, IL-1 is implicated in regulating the discharge 
of PGE2 and of leukotrienes (LTs) [6], which are ei- 
cosanoid mediators of inflammation. The modula- 
tory role of PGE2 in opposing the effect of LTs on 
the involvement of macrophages in the inflammato- 
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ry process was proposed several years ago [7]. Simi- 
larly, interactions between eicosanoids and 
cytokines (IL-l, TNFo0, contribute to the regulation 
of macrophage and monocyte functions [4]. Because 
the activation state of the macrophage is of pivotal 
importance for the role of this cell in both events (in- 
flammation and defence against umors), the media- 
tors of inflammation which are involved in the acti- 
vation of macrophages may constitute the link 
between the two events. 
This minireview is based mainly on the data ob- 
tained in our laboratories during the last six years on 
the role of macrophage inflammatory mediators 
(cytokines and eicosanoids) in the expression of an- 
titumor cytostatic activity, with special emphasis on 
the interactions between various macrophage 
products. This in view of the fact that cytokines and 
eicosanoids (leukotrienes and prostaglandins) regu- 
late their own and each other's release. It is not within 
the scope of this article to discuss all the vast litera- 
ture on the various activities of macrophages and/or 
inflammatory mediators. In this context, the reader 
is referred to extensive, detailed reviews published in 
recent years [4-6]. 
3. Eicosanoids and cytokines regulate their own 
and each other's release 
Eicosanoids, products of arachidonic acid (AA) 
metabolism, feed back onto the macrophage and 
modulate their own release. The observation that IL- 
l interferes with the release of lipoxygenase products 
[8], renders the situation even more complicated. Ta- 
ble 1 is an attempt to provide aguide in the complex- 
ity of events. The most salient points can be high- 
lighted as follows. The earlier knowledge that the re- 
lease of LTB 4 is enhanced by stimulation of calcium 
flux by A23187 and reduced by inhibitors of lipox- 
TABLE 1 
Autoregulation of mediator elease from macrophages. 
Released product Effect of exogenous compound on release 
Increase by Decrease by 
Peptidoleukotrienes a IL-1 [8] 
(LTC 4 or LTD4) 
LTB4a A23187 [10, l l] 
Aspirin, indomethacin [10] 
PGE 2 
PGI2b 
LTC4, LTD 4 [12, 13] 
db-cAMP [10] 




LTD [12] PGE2, db-cAMP [14] 
A23187 [11] 
TxA2C LTD [12] PGE2, db-cAMP 
A23187 Ill] [14, 10] 
ILl d LTB 4 [16]; TNFa [18] PGE 2 [15]; PGI 2 
LPS [34] [15] 
Indomethacin 
piroxicam, ibuprofen [15] 
TNFc~ d LPS [19]; low conc. PGE2e High conc. PGE2f, 
[201 [20] 
a Basal level is below detection level; A23187-induced stimulation of calcium flux is used to promote release for investigating regulatory 
events, b Measured as the metabolite 6-keto-PGF1, r c Measured as TxB 2. d LPS-stimulated release is used to measure regulatory in- 
fluences, e < 10 ng/ml, f > l0 ng/ml. Inhibition of release of cyclooxygenase products by aspirin, indomethacin, etc., is textbook 
knowledge and omitted from this table. 
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ygenase, has now been extended with the observation 
that PGE 2 counteracts the discharge of lipox- 
ygenase products. This effect of PGE 2 is mediated 
through elevation of intracellular cyclic AMP, which 
reduces the amount of free AA available to different 
enzymes, including lipoxygenase. Nonsteroidal nti- 
inflammatory drugs (NSAIDs), through removal of 
the regulatory effect of PGE2, promote the release 
of lipoxygenase metabolites [9-11]. Furthermore, 
LTs were shown to promote the release of cycloox- 
ygenase metabolites, PGE 2 included [12, 13]. In the 
view that PGE 2 would in turn inhibit the release of 
LTs [10], the action of the latter is a homeostatic self- 
limiting process. PGE2-induced elevation of in- 
tracellular cyclic AMP and the mimicry of this event 
by exogenous dibutyryl cAMP decreases not only 
the calcium flux enhancement of LTB 4, but also 
that of cyclooxygenase metabolites [14]. According- 
ly, the eicosanoid secreting function of macrophages 
is positively related to the activity of the lipox- 
ygenase pathway and in negative relation to the syn- 
thesis viz. discharge of the cyclooxygenase metabo- 
lite PGE2: LTs enhance the release of eicosanoids 
(thus mimicking the effect of A23187), whereas 




Nordihydro- ~ 5  guaiaretic acid .... 
(NDGA) 
Indomethacin _. mor cell 
and lipoxygenase metabolites being each other's op- 
ponents in macrophage function takes on new 
dimensions in the light of recent findings which 
show that LPS-stimulated secretion of IL-1, itself a 
stimulator of PGE 2 production [15], is promoted by 
LTB4 and LTD 4 [16]. NSAIDs were reported to en- 
hance the discharge of IL-1, conceivably through 
removing endogenous PGE2 [15]. But others 
showed that PGE 2 has no effect on IL-1 production, 
but interferes with the bioassay of IL-1 [17]. Besides 
the homeostatic negative feedback that involves ei- 
cosanoids controlling their own release and their 
mutual interaction with the release of IL-1, it appears 
that there is a regulatory circle between cytokines as 
well. At least, TNFot was shown to enhance the re- 
lease of IL-1 [18], whereas LPS stimulates the produ- 
cion not only of IL-1, but also of TNFct [19]. Howev- 
er, PGE 2 has a dual effect on TNFct secretion, low 
doses having a stimulatory influence and high con- 
centrations suppressing this event [20]. This would 
indicate that PGE 2 regulation of TNFct secretion is
dissimilar to PGE 2 control of IL discharge. Howev- 
er, the low concentrations of PGE 2, having caused 
increased production of TNFoG were not examined 
for their effect on IL-1 secretion. Accordingly, adual 
(b) 
LTB 4 
AA861 .... o 
/ . . . . . .  : 
. . . . .  
+ 4-  P815 Ionophore Ca" 4--.- i tumor cell 
A23187 " ~  i "~' 
db-cAMP 
Fig. 1. Solid arrows, stimulatory influences; broken arrows, inhibitory influences. (a) Lipoxygenase products either added exogenously 
to macrophages or produced in abundance following indomethacin treatment, enhance cytostasis. PGE 2 counteracts the release of lipox- 
ygenase products and accordingly inhibits the cytostatic function. This effect of PGE 2 is mediated through elevation of intracellular cyclic 
AMP which reduces the amount of arachidonic acid (AA) available to different enzymes, including lipoxygenase. Thus, PGE 2 reduces 
the release of LTB 4 and other leukotrienes. Indomethacin, through removal of PGE 2, promotes the synthesis of lipoxygenase products 
and accordingly enhances cytostasis. The indomethacin-enhanced cytostasis is counteracted by NDGA-induced inhibition of lipoxygenase. 
For original papers ee [9, 10, 23]. (b) Stimulation of calcium flux by A23187 enhances the cytostatic function of macrophages toward 
tumor cells. This effect of A23187 is mediated via release of LTB 4, which promotes cytostasis. The ~pecific lipoxygenase inhibitor AA861 
counteracts both the release of LTB 4 and cytostasis. Calcium flux stimulates phospholipase activity, resulting in enlarged amounts of 
free AA. Mimicry of endogenous cyclic AMP by exogenous dibutyryl cyclic AMP (db-cAMP) counteracts the effect of the calcium iono- 
phore. In similarity to indomethacin-enhanced cytostasis, also the calcium flux-enhanced cytostasis requires a promoted release of lipox- 
ygenase products. For original papers ee [10, 11, 22]. 
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effect of PGE 2 on IL-1 secretion cannot be exclud- 
ed. Furthermore, macrophages also release cytostat- 
ic factors other than IL-1 or TNFot [21]. It is not 
known whether the release of these other factors is 
under the control of eicosanoids. Nevertheless, to 
understand the cytokine-eicosanoid regulation of 
the macrophage cytostatic function, the network as 
discussed above may serve as a blueprint, as will be 
shown in the sections which follow. 
4. Lipoxygenase pathway favors cell-to-cell contact 
cytostasis 
Increasing evidence has accumulated during the 
last few years indicating that the antitumor activity 
of macrophages in a cell-to-cell contact system is 
regulated by eicosanoid products [9, 11, 22, 23]. 
These results were obtained by co-culturing macro- 
phages with target cells. A pitfall of this method 
might be the release by macrophages of a soluble fac- 
tor which inhibits uptake of thymidine by target cells 
while not affecting their rate of proliferation I24]. 
However, we used as target cells the murine tumor 
cell lines MOPC-315 plasmacytoma and P815 
mastocytoma, which were susceptible only to direct 
contact with macrophages but not to their soluble 
products. The role of leukotrienes in promotion of 
antitumor cytostasis by macrophages is illustrated in
Fig. la and b. Treatment of macrophages with in- 
TABLE 2 
domethacin (which promotes LTB 4 production 
[10]), or exogenous addition of LTs (LTD4 or LTB4) 
to co-cultures of macrophages and tumor cells en- 
hanced the antitumor cytostasis by macrophages, 
whereas a lipoxygenase inhibitor (NDGA) prevented 
theantitumor activity(Fig, la). Stimulation of calci- 
um flux by the calcium ionophore A23187 enhanced 
both cytostatic function of macrophages and release 
of LTB4, whereas both release of LTB 4 and cytosta- 
sis were prevented by the specific lipoxygenase inhib- 
itor AA861 (Fig. lb). On the other hand, mimicry of 
endogenous cyclic AMP (increased production 
related to increase in prostaglandin biosynthesis) by 
exogenous dibutyryl cyclic AMP (db-cAMP), coun- 
teracts the effect of A23187 in induction of 
cytostasis. 
5. Interactions between cytokines and eicosanoids 
on tumor cell growth 
The antitumor activity of macrophage cytokines 
IL-1 and of TNFo~ is well established [3, 25, 26]. We 
found that the murine WEHI-3B tumor was highly 
sensitive to IL-1 [27] and less sensitive to TNFa. The 
availability of a tumor-cell sensitive to cell-free mac- 
rophage cytokines, allowed us to investigate interac- 
tions between cell-free macrophage cytokines and ei- 
cosanoids in inhibiting tumor cell growth (Table 2). 
Effect on tumor growth of cytokine mediators produced by the macrophage and their interactions with eicosanoids. 
Treatment 
Simultaneous a Preconditioning 
Compound b Inhibition c Prior d Simultaneous Inhibition 
IL-I + IL-1 None 0 
IL-I + PGE 2 + + IL-I PGE z + + 
IL-I + PGI 2 + + IL-I PGI 2 + 
IL-1 + LTC 4 0 
TNF~ + TNFot None 0 
TNFc~ + PGE 2 + + TNFc~ PGE 2 + + 
TNFot + PGI 2 + TNFa PGI 2 0 
a Compounds added simultaneously with WEHI-3B tumor cells to culture medium, b IL-I: 1000 U/ml; TNFa: 100 U/ml; PGE2: 
10-6 M; PGI2:4 × 10- s M; LTC4: 10-7 M. PGE 2 alone has a slight cytostatic effect. LTC 4 and PGI 2 alone had no effect at the concen- 
trations used. Higher concentrations of PGI 2 markedly inhibited growth, c Inhibition calculated by comparison with 3H-thymidine in- 
corporation i  corresponding cultures of untreated tumor cells: rating of inhibition: 0 -  19%, 0; 20-  39%, + ; >40%, + +.  d Tumor 
cells were first incubated for 1 h with the compound and then washed before resetting in culture medium. Prior treatment with either 
one of the cytokines did not precondition to subsequent exposure to the same cytokine or to the other cytokine. Data on simultaneous 
treatment with IL-I and eicosanoids are from reference 27; other data from reference 28. 
298 
The cytostatic activity of HrlL-1 toward WEHI-3B 
tumor cells was enhanced by PGE 2 or prostacyclin 
(PGI2), whereas simultaneous addition of LTC4 
prevented cytostasis by IL-1 [9]. A similar synergistic 
effect was found between HrTNFot and PGE 2, but 
not between TNFot and PGI [28]. Prior treatment 
with either IL-1 or TNFa rendered the tumor cells 
susceptible to PGE 2, whereas only prior contact 
with IL-1 rendered the cells susceptible toPGI 2 [28]. 
Therefore, whereas exogenous addition of 
prostaglandins was shown to inhibit the release of 
IL-1 [15, 16], these two products interact synergisti- 
cally in enhancing antitumor cytostasis, when they 
are added as cell-free compounds to tumor-cell cul- 
tures. Moreover, exogenous addition of a leu- 
kotriene, LTC4, antagonized the cytostatic activity 
of IL-1, whereas endogenous release of leukotrienes 
favours cell-to-cell cytostasis [9, 11, 22, 23] and 
production of IL-1 [16]. In contrast to IL-1, TNFot 
, Ps  
PGE2 - ~ . ,~  • - - . : '~,r . . "  I 
Fig. 2. Schematic view of some factors involved in the antitumor 
cytostatic function of macrophages from inflammatory environ- 
ment. A premise in this concept is that the antitumor function 
of macrophages is unconditionally linked to activation of these 
cells. The macrophage cooperation with T cells is of importance, 
because the T cell product interferon-3, isa powerful activator of 
macrophages. Activated macrophages vigorously secrete IL-l and 
TNF, which can inhibit the growth of several tumor cell lines. 
Infectious-inflammatory sites contain substantial mounts of 
bacterial endotoxins ( ymbolized here as LPS), which stimulate 
the secretion of IL-1 and TNE Still another factor that causes the 
macrophage to secrete cytokines is the lipoxygenase product 
LTB 4 which is abundantly present at sites of inflammation. The 
cyclooxygenase metabolite PGE 2 has multiple roles in macro- 
phage antitumor cytostasis: it counteracts the activation of mac- 
rophages and inhibits the secretion of cytokines. On the other 
hand PGE 2 appears to directly inhibit he growth of some tumor 
cell lines and may have potentiating interactions with effects of 
the cytokines. This oversimplified model, in common with most 
models, is a poor replica of reality. 
did not act synergistically with PGI 2 [28]. The 
difference between IL-1 and TNFa in interaction 
with prostaglandins may be due to differences in their 
mechanism ofactivity and/or to differences between 
PGE 2 and PGI 2 in their mode of activity. Differ- 
ences between the activity of PGEz and PGI2 were 
reported in context of regulation of macrophage- 
mediated tumor killing [29]. Furthermore PGE 2 it- 
self acted in different ways in various experimental 
conditions. Increase in PGE2 production i  activat- 
ed macrophages resulted in inhibition of their 
tumoricidal ctivity, whereas production of high lev- 
els of PGE 2 by resident and elicited macrophages 
was associated with increase in antitumor activity 
[30]. These results are all the more in variance with 
others because licited macrophages are usually 
found to produce relatively low amounts of PGE 2 
[31]. 
6. Ex-vivo human inflammatory macrophages 
The set of observations presented above led us to 
conclude that mediators of inflammation have a 
two-fold implication for the function of macro- 
phages. First, when the balance of eicosanoid 
production profile of macrophages is tipped in favor 
of the lipoxygenase pathway, the macrophage be- 
comes activated and displays improved cytostasis [9, 
11]. The expression of this function may be even fur- 
ther improved by exposing the macrophage to a leu- 
kotriene (LTC 4 or LTD4) [22, 23]. Second, the direct 
antitumor cytostasis of macrophage-derived 
cytokines (IL-1 and TNF~), can be modified by exo- 
genous addition of eicosanoids in absence of mac- 
rophages, as published earlier (Ref. 27 and Table 2). 
Some macrophage-derived cytokines are recognized 
as mediators of inflammation [5] and as exerting an- 
titumor activity [25, 26]. Therefore, we addressed the 
question whether macrophages harvested from an 
inflammatory environment would express more an- 
titumor cytostatic activity than macrophages har- 
vested from an inflammation-free environment [32]. 
Human macrophages collected from dialysis bags 
during peritoneal inflammation exhibited markedly 
enhanced cytostatic activity (Table 3). Improved 
cytostasis was evident toward three target cell lines: 
one requiring cell-to-cell contact (MOPC-315), an- 
other which is sensitive to both IL-1 and TNFot 
(WEHI-3B), and a third cell line susceptible to 
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TABLE 3 
Inf lammatory environment enhances the antitumor cytostasis of human peritoneal macrophages a. 
Target cell line Inhibition of tumor-cell growth by macrophages of different environments b 
Non-inf lammatory Inf lammatory 
Unstimulated LPS c stimulated Unstimulated LPS c stimulated 
MOPC-315 0 0 + + + + 
WEHI-3B 0 + + + + 
L929 0 + + + + + 
a Human peritoneal macrophages were collected from patients on continuous peritoneal ambulatory dialysis (CAPD). b Macro- 
phage/target-cell ratio was 100/l, using the coculture method rating of inhibition: 0 -  19o70, 0; 20-39o70, + ; >40%,  + +.  c LPS, 
0.5 #g/ml.  For more details see ref. 32. 
TNFo~ only (L929: transformed fibroblast line). Hu- 
man peritoneal macrophages from an inflammatory 
environment display reduced basal release of PGE 2, 
a circumstance that favors the activation of macro- 
phages. Reduction in PGE 2 production was also 
found to enhance cytostasis toward MOPC-315 
tumor cells of mouse peritoneal macrophages [9, 
23]. The fact that human peritoneal macrophages 
from an inflammatory environment exhibit cytosta- 
sis toward murine tumor cells, indicates that species 
differences play in this event a subordinate role. The 
present results (Table 3) also show that LPS en- 
hances the cytostatic activity toward WEHI-3B and 
L929 cells of human macrophages from an inflam- 
matory environment. I  is worth mention in this con- 
text that LPS is a powerful stimulant of IL-1 dis- 
charge from human peritoneal macrophages, 
particularly those from an inflammatory environ- 
ment [33], and that LPS induces production of 
TNFo~ [19]. Macrophages from inflammatory en- 
vironments have a low level of cyclic AMP [34], and 
it is conceivable that their content of cyclic GMP is 
relatively high. A prevalence of cyclic GMP was re- 
cently shown to be associated with the release of 
TNFa [20]. 
tivity of macrophages, not only by inhibiting en- 
dogenous production of PGE 2, but also by increas- 
ing the production of leukotrienes. The use of tumor 
lines susceptible to cell-free cytokines IL-1 and 
TNFot enabled us to show interactions between exo- 
genous cytokines and prostaglandins in the context 
of antitumor cytostatic activity. It is Of interest in 
this respect that prostaglandins acted synergistically 
with macrophage cytokines in increasing antitumor 
activity, whereas an increase in endogenous produc- 
tion of prostaglandins is assumed to be correlated 
with a decrease in antitumor activity. 
These results apply to in vitro or ex vivo systems 
of determination of antitumor activity. It might be 
of interest to determine to what extent mutual inter- 
actions between macrophage cytokines and eicosa- 
noids play a role in the expression of antitumor ef- 
fects of macrophages in vivo. Such information is 
not yet available. Nevertheless, our findings provide 
a link between the inflammation process and the an- 
titumor activity of macrophages in the antitumor 
activity of macrophages in tumor-bearing in- 
dividuals. 
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